LUCD – lucid diagnostics inc. (US:NASDAQ)
Stock Stats
News
Lucid Diagnostics (NASDAQ:LUCD) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $8.25. They now have a "buy" rating on the stock.
Lucid Diagnostics (NASDAQ:LUCD) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest shareholders are individual investors with 38% ownership, public companies own 30% [Yahoo! Finance]
Lucid Diagnostics (NASDAQ:LUCD) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Form S-3 Lucid Diagnostics Inc.
Form 8-K Lucid Diagnostics Inc. For: Nov 12
Form 10-Q Lucid Diagnostics Inc. For: Sep 30
Form SCHEDULE 13D/A Lucid Diagnostics Inc. Filed by: PAVmed Inc.
Form 4 Lucid Diagnostics Inc. For: Oct 06 Filed by: PALUMBO JOHN R
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.